4 completed, 1 not yet recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow this drug Literature Review of HIV Envelope Protein gp120 trials Research Report on HIV Envelope Protein gp120
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant - HIV Prevention | Phase 2 | Not yet recruiting | Worcester HIV Vaccine | 126 | 2026-09-01 | 2026-06-30 |
| Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant - HIV Infections | Phase 1 | Completed | Worcester HIV Vaccine | 42 | 2021-07-08 | 2024-04-09 |
| Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2018-03-16 | 2022-04-25 |
| Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults ALVAC-HIV, AIDSVAX B/E, Placebo for ALVAC-HIV - HIV Infection | Phase 1 | Completed | HIV Vaccine Trials Network | 202 | 2013-06-18 | 2019-06-21 |
| Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART) HIV gp120/NefTat/AS02A Vaccine - HIV Infections | Phase 1 | Completed | Marcus Altfeld, M.D., Ph.D. | 20 | 2005-06-01 | 2010-02-15 |
HIV Infections (4)
Worcester HIV Vaccine (2) · HIV Vaccine Trials Network (1) · Marcus Altfeld, M.D., Ph.D. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (4) · South Africa (2)
Conasagrie Nair, PhD, MD (1) · Glenda Gray, MD (1) · Ian Frank (1) · Marcus Altfeld, MD/PhD (1) · Mathias Lichterfeld, MD/PhD (1) · Stephen Walsh, PhD, MD (1) · Turner Overton (1)
PMID 40190112, PMID 25401780, PMID 31999736, PMID 38692824, PMID 41212034